Vaccine Information: GARDASIL (Page 4 of 8)
14.2 Prophylactic Efficacy – HPV Types 6, 11, 16, and 18 in Boys and Men 16 through 26 Years of Age
The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population. This population consisted of boys and men who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naïve (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month postdose 3 (Month 7). Efficacy was measured starting after the Month 7 visit.
GARDASIL was efficacious in reducing the incidence of genital warts related to vaccine HPV types 6 and 11 in those boys and men who were PCR negative and seronegative at baseline (Table 12). Efficacy against penile/perineal/perianal intraepithelial neoplasia (PIN) grades 1/2/3 or penile/perineal/perianal cancer was not demonstrated as the number of cases was too limited to reach statistical significance.
Endpoint | GARDASIL | AAHS Control | % Efficacy (95% CI) | ||
---|---|---|---|---|---|
N † | Number of cases | N | Number of cases | ||
CI = Confidence Interval | |||||
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate | |||||
| |||||
External Genital Lesions HPV 6-, 11-, 16-, or 18- related | |||||
External Genital Lesions | 1394 | 3 | 1404 | 32 | 90.6 (70.1, 98.2) |
Condyloma | 1394 | 3 | 1404 | 28 | 89.3 (65.3, 97.9) |
PIN 1/2/3 | 1394 | 0 | 1404 | 4 | 100.0 (-52.1, 100.0) |
14.3 Prophylactic Efficacy – Anal Disease Caused by HPV Types 6, 11, 16, and 18 in Boys and Men 16 through 26 Years of Age in the MSM Sub-study
A sub-study of Study 5 evaluated the efficacy of GARDASIL against anal disease (anal intraepithelial neoplasia and anal cancer) in a population of 598 MSM. The primary analyses of efficacy were conducted in the per-protocol efficacy (PPE) population of Study 5.
GARDASIL was efficacious in reducing the incidence of anal intraepithelial neoplasia (AIN) grades 1 (both condyloma and non-acuminate), 2, and 3 related to vaccine HPV types 6, 11, 16, and 18 in those boys and men who were PCR negative and seronegative at baseline (Table 13).
HPV 6-, 11-, 16-, or 18- related Endpoint | GARDASIL | AAHS Control | % Efficacy (95% CI) | ||
---|---|---|---|---|---|
N † | Number of cases | N | Number of cases | ||
CI = Confidence Interval | |||||
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate | |||||
| |||||
AIN 1/2/3 | 194 | 5 | 208 | 24 | 77.5 (39.6, 93.3) |
AIN 2/3 | 194 | 3 | 208 | 13 | 74.9 (8.8, 95.4) |
AIN 1 | 194 | 4 | 208 | 16 | 73.0 (16.3, 93.4) |
Condyloma Acuminatum | 194 | 0 | 208 | 6 | 100.0 (8.2, 100.0) |
Non-acuminate | 194 | 4 | 208 | 11 | 60.4 (-33.5, 90.8) |
14.4 Population Impact in Girls and Women 16 through 26 Years of Age
Effectiveness of GARDASIL in Prevention of HPV Types 6-, 11-, 16-, or 18-Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Exposure to Vaccine HPV Types
The clinical trials included girls and women regardless of current or prior exposure to vaccine HPV types, and additional analyses were conducted to evaluate the impact of GARDASIL with respect to HPV 6-, 11-, 16-, and 18-related cervical and genital disease in these girls and women. Here, analyses included events arising among girls and women regardless of baseline PCR status and serostatus, including HPV infections that were present at the start of vaccination as well as events that arose from infections that were acquired after the start of vaccination.
The impact of GARDASIL in girls and women regardless of current or prior exposure to a vaccine HPV type is shown in Table 14. Impact was measured starting 1 month Postdose 1. Prophylactic efficacy denotes the vaccine’s efficacy in girls and women who are naïve (PCR negative and seronegative) to the relevant HPV types at Day 1. Vaccine impact in girls and women who were positive for vaccine HPV infection, as well as vaccine impact among girls and women regardless of baseline vaccine HPV PCR status and serostatus are also presented. The majority of CIN and genital warts, VIN, and VaIN related to a vaccine HPV type detected in the group that received GARDASIL occurred as a consequence of HPV infection with the relevant HPV type that was already present at Day 1.
There was no clear evidence of protection from disease caused by HPV types for which girls and women were PCR positive regardless of serostatus at baseline.
Endpoint | Analysis | GARDASIL or HPV 16 L1 VLP Vaccine | AAHS Control | % Reduction(95% CI) | ||
---|---|---|---|---|---|---|
N | Cases | N | Cases | |||
CI = Confidence Interval | ||||||
N = Number of individuals who have at least one follow-up visit after Day 1 | ||||||
Note 1: The 16- and 18-related CIN 2/3 or AIS composite endpoint included data from studies 1, 2, 3, and 4. All other endpoints only included data from studies 2, 3, and 4. | ||||||
Note 2: Positive status at Day 1 denotes PCR positive and/or seropositive for the respective type at Day 1. | ||||||
Note 3: Table 14 does not include disease due to non-vaccine HPV types. | ||||||
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate | ||||||
| ||||||
HPV 16- or 18-related CIN 2/3 or AIS | Prophylactic Efficacy * | 9346 | 4 | 9407 | 155 | 97.4 (93.3, 99.3) |
HPV 16 and/or HPV 18 Positive at Day 1† | 2870 | 142 | 2898 | 148‡ | —§ | |
Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18¶ | 9836 | 146 | 9904 | 303 | 51.8 (41.1, 60.7) | |
HPV 16- or 18-related VIN 2/3 or VaIN 2/3 | Prophylactic Efficacy * | 8642 | 1 | 8673 | 34 | 97.0 (82.4, 99.9) |
HPV 16 and/or HPV 18 Positive at Day 1† | 1880 | 8 | 1876 | 4 | — § | |
Girls and Women Regardless of Current or Prior Exposure to HPV 16 or 18¶ | 8955 | 9 | 8968 | 38 | 76.3 (50.0, 89.9) | |
HPV 6-, 11-, 16-, 18-related CIN (CIN 1, CIN 2/3) or AIS | Prophylactic Efficacy * | 8630 | 16 | 8680 | 309 | 94.8 (91.5, 97.1) |
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1† | 2466 | 186# | 2437 | 213# | — § | |
Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types ¶ | 8819 | 202 | 8854 | 522 | 61.5 (54.6, 67.4) | |
HPV 6-, 11-, 16-, or 18-related Genital Warts | Prophylactic Efficacy * | 8761 | 10 | 8792 | 252 | 96.0 (92.6, 98.1) |
HPV 6, HPV 11, HPV 16, and/or HPV 18 Positive at Day 1† | 2501 | 51Þ | 2475 | 55 Þ | — § | |
Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types ¶ | 8955 | 61 | 8968 | 307 | 80.3 (73.9, 85.3) | |
HPV 6- or 11-related Genital Warts | Prophylactic Efficacy * | 7769 | 9 | 7792 | 246 | 96.4 (93.0, 98.4) |
HPV 6 and/or HPV 11 Positive at Day 1† | 1186 | 51 | 1176 | 54 | — § | |
Girls and Women Regardless of Current or Prior Exposure to Vaccine HPV Types ¶ | 8955 | 60 | 8968 | 300 | 80.1 (73.7, 85.2) |
Effectiveness of GARDASIL in Prevention of Any HPV Type Related Genital Disease in Girls and Women 16 Through 26 Years of Age, Regardless of Current or Prior Infection with Vaccine or Non-Vaccine HPV Types
The impact of GARDASIL against the overall burden of dysplastic or papillomatous cervical, vulvar, and vaginal disease regardless of HPV detection, results from a combination of prophylactic efficacy against vaccine HPV types, disease contribution from vaccine HPV types present at time of vaccination, the disease contribution from HPV types not contained in the vaccine, and disease in which HPV was not detected.
Additional efficacy analyses were conducted in 2 populations: (1) a generally HPV-naïve population (negative to 14 common HPV types and had a Pap test that was negative for SIL [Squamous Intraepithelial Lesion] at Day 1), approximating a population of sexually-naïve girls and women and (2) the general study population of girls and women regardless of baseline HPV status, some of whom had HPV-related disease at Day 1.
Among generally HPV-naïve girls and women and among all girls and women in the study population (including girls and women with HPV infection at Day 1), GARDASIL reduced the overall incidence of CIN 2/3 or AIS; of VIN 2/3 or VaIN 2/3; of CIN (any grade) or AIS; and of Genital Warts (Table 15). These reductions were primarily due to reductions in lesions caused by HPV types 6, 11, 16, and 18 in girls and women naïve (seronegative and PCR negative) for the specific relevant vaccine HPV type. Infected girls and women may already have CIN 2/3 or AIS at Day 1 and some will develop CIN 2/3 or AIS during follow-up, either related to a vaccine or non-vaccine HPV type present at the time of vaccination or related to a non-vaccine HPV type not present at the time of vaccination.
Endpoints Caused by Vaccine or Non-vaccine HPV Types | Analysis | GARDASIL | AAHS Control | % Reduction(95% CI) | ||
---|---|---|---|---|---|---|
N | Cases | N | Cases | |||
CI = Confidence Interval | ||||||
AAHS Control = Amorphous Aluminum Hydroxyphosphate Sulfate | ||||||
| ||||||
CIN 2/3 or AIS | Prophylactic Efficacy * | 4616 | 77 | 4680 | 136 | 42.7 (23.7, 57.3) |
Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types † | 8559 | 421 | 8592 | 516 | 18.4 (7.0, 28.4) | |
VIN 2/3 and VaIN 2/3 | Prophylactic Efficacy * | 4688 | 7 | 4735 | 31 | 77.1 (47.1, 91.5) |
Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types † | 8688 | 30 | 8701 | 61 | 50.7 (22.5, 69.3) | |
CIN (Any Grade) or AIS | Prophylactic Efficacy * | 4616 | 272 | 4680 | 390 | 29.7 (17.7, 40.0) |
Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types † | 8559 | 967 | 8592 | 1189 | 19.1 (11.9, 25.8) | |
Genital Warts | Prophylactic Efficacy * | 4688 | 29 | 4735 | 169 | 82.8 (74.3, 88.8) |
Girls and Women Regardless of Current or Prior Exposure to Vaccine or Non-Vaccine HPV Types † | 8688 | 132 | 8701 | 350 | 62.5 (54.0, 69.5) |
VxLabels.com provides trustworthy package insert and label information about marketed drugs and vaccines as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by VxLabels.com. Every individual vaccine label and package insert entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.